Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 13/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 10/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21471793 | 0.90 | AVPR2 (0.40) | AVPR2AVPR1A | |
| SCHEMBL20619707 | 0.90 | AVPR2 (0.42) | AVPR2AVPR1ASCN10A | |
| SCHEMBL21471665 | 0.89 | AVPR2 (0.35) | AVPR2AVPR1A | |
| SCHEMBL21471670 | 0.89 | AVPR2 (0.37) | AVPR2AVPR1A | |
| SCHEMBL20620181 | 0.89 | AVPR2 (0.41) | AVPR2AVPR1ASCN10ARAF1BRAF | |
| SCHEMBL20619508 | 0.89 | AVPR2 (0.41) | AVPR2AVPR1A | |
| SCHEMBL21471782 | 0.89 | AVPR2 (0.40) | AVPR2AVPR1A | |
| SCHEMBL21471744 | 0.89 | AVPR2 (0.41) | AVPR2AVPR1A | |
| SCHEMBL20619509 | 0.88 | AVPR2 (0.43) | AVPR2AVPR1A | |
| SCHEMBL20619924 | 0.88 | AVPR2 (0.39) | AVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2019199908-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | AVPR2 969/4885GRM1 2669/4885GRM4 3540/4885 |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | AVPR2 969/4885GRM1 2669/4885GRM4 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.